Relmada Therapeutics (RLMD) Total Liabilities (2012 - 2026)
Relmada Therapeutics (RLMD) reported Total Liabilities of $16.6 million for Q1 2026, up 217.44% year-over-year from $5.2 million in Q1 2025, and up 121.99% on a QoQ basis from $7.5 million in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Total Liabilities data on file, last reported at $16.6 million in Q1 2026.
- Quarterly Total Liabilities rose 217.44% year-over-year to $16.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.6 million (up 217.44% YoY) and the FY2025 annual result came in at $7.5 million, down 27.24% from the prior year.
- Total Liabilities advanced to $16.6 million in Q1 2026 per RLMD's latest filing, from $7.5 million in the prior quarter.
- Across five years, Total Liabilities topped out at $20.8 million in Q3 2022 and bottomed at $5.2 million in Q2 2025.
- The 5-year median for Total Liabilities is $10.3 million (2024), against an average of $11.1 million.
- The widest annual swing landed in 2023, when Total Liabilities slumped 59.46%; it then jumped 217.44% in 2026.
- Tracing RLMD's Total Liabilities over 5 years: stood at $12.5 million in 2022, then dropped by 2.2% to $12.2 million in 2023, then slipped by 15.57% to $10.3 million in 2024, then declined by 27.24% to $7.5 million in 2025, then soared by 121.99% to $16.6 million in 2026.
- Per Business Quant, the three latest RLMD Total Liabilities figures stand at $16.6 million (Q1 2026), $7.5 million (Q4 2025), and $5.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 16.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.63 Mn |
| Dec 31, 2025 | 7.49 Mn |
| Sep 30, 2025 | 5.41 Mn |
| Jun 30, 2025 | 5.17 Mn |
| Mar 31, 2025 | 5.24 Mn |
| Dec 31, 2024 | 10.30 Mn |
| Sep 30, 2024 | 8.10 Mn |
| Jun 30, 2024 | 9.54 Mn |
| Mar 31, 2024 | 12.36 Mn |
| Dec 31, 2023 | 12.19 Mn |
| Sep 30, 2023 | 8.42 Mn |
| Jun 30, 2023 | 10.70 Mn |
| Mar 31, 2023 | 10.10 Mn |
| Dec 31, 2022 | 12.47 Mn |
| Sep 30, 2022 | 20.78 Mn |
| Jun 30, 2022 | 18.92 Mn |
| Mar 31, 2022 | 15.41 Mn |
| Dec 31, 2021 | 15.06 Mn |
| Sep 30, 2021 | 18.25 Mn |
| Jun 30, 2021 | 13.92 Mn |
| Mar 31, 2021 | 12.72 Mn |
| Dec 31, 2020 | 12.60 Mn |
| Sep 30, 2020 | 3.39 Mn |
| Jun 30, 2020 | 2.33 Mn |
| Mar 31, 2020 | 2.26 Mn |
| Dec 31, 2019 | 1.46 Mn |
| Sep 30, 2019 | 2.54 Mn |
| Jun 30, 2019 | 2.61 Mn |
| Mar 31, 2019 | 2.13 Mn |
| Dec 31, 2018 | 1.86 Mn |
| Sep 30, 2018 | 10.30 Mn |
| Jun 30, 2018 | 8.56 Mn |
| Mar 31, 2018 | 7.11 Mn |
| Dec 31, 2017 | 5.85 Mn |
| Sep 30, 2017 | 4.15 Mn |
| Jun 30, 2017 | 1.38 Mn |
| Mar 31, 2017 | 1.37 Mn |
| Dec 31, 2016 | 1.55 Mn |
| Sep 30, 2016 | 2.35 Mn |
| Jun 30, 2016 | 3.20 Mn |
| Mar 31, 2016 | 2.51 Mn |
| Dec 31, 2015 | 4.84 Mn |
| Sep 30, 2015 | 6.65 Mn |
| Jun 30, 2015 | 15.58 Mn |
| Mar 31, 2015 | 25.36 Mn |
| Dec 31, 2014 | 28.20 Mn |
| Sep 30, 2014 | 48.57 Mn |
| Jun 30, 2014 | 26.87 Mn |
| Nov 30, 2013 | 40,331.00 |
| Aug 31, 2013 | 33,666.00 |
| May 31, 2013 | 26,026.00 |
| Feb 28, 2013 | 12,002.00 |
| Aug 31, 2012 | 6,996.00 |